Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Feb 2018

Zuo Tao, Wong Serena, Buza Natalia, Hui Pei

Abstract excerpt

In contrast to non-invasive extraovarian implants, invasive implants of ovarian serous borderline tumor/atypical proliferative serous tumor are associated with adverse outcome and have been reclassified as low-grade serous carcinoma. Mutations of KRAS and/or BRAF have been reported in up to 50% of serous borderline tumor/atypical proliferative serous tumor. We investigated KRAS and BRAF mutation frequencies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Invasiveness

Share to Ovarian Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Young Adult

Source

Identifiers

PMID: 29027536
DOI: 10.1038/modpathol.2017.121

Genes

KRAS
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.PMID 29027536Read ↗

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Semantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.Semantic proximity Read ↗

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Semantic proximity Read ↗

Low-grade serous ovarian cancer: A review.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.Semantic proximity Read ↗

Serous borderline tumours of the ovary.Semantic proximity Read ↗

Seromucinous Tumors of the Ovary. What's in a Name?Semantic proximity Read ↗

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.